DCLK1 and renal cell carcinoma: Finally, in renal cell carcinoma, siRNA-mediated knockdown of DCLK1 significantly sensitized co-cultured endothelial cells to the vascular endothelial growth factor receptor (VEGFR) inhibitor sunitinib in an in vitro angiogenesis assay, demonstrating that expression of DCLK1 on neoplastic cells directly modulates this component of the tumor microenvironment.